Ultra-hypofractionated versus conventional chemoradiation for newly diagnosed glioblastoma: Survival and toxicity results of a multicenter randomized trial.
Anouk M de Jong, Arthur T J van der Boog, Gerda Wester et al.
✦ AI-curated · Sources linked
In 30 seconds
This phase III randomized trial evaluated the non-inferiority of ultra-hypofractionated chemoradiation (6x6Gy) versus standard chemoradiation (30x2Gy) in adults with newly diagnosed glioblastoma. The study found that median overall survival was significantly shorter in the ultra-hypofractionated group at 13.0 months compared to 21.0 months for the standard treatment.
Key findings
- Median overall survival was 13.0 months for ultra-hypofractionation versus 21.0 months for standard treatment.
- Mortality after 6 months was higher in the ultra-hypofractionated group (HR 2.54, p < 0.001).
- Radiation necrosis or pseudoprogression occurred in 47.8% of the ultra-hypofractionated group compared to 16.2% in the standard group.
Why it matters
The findings indicate that ultra-hypofractionated chemoradiation is associated with inferior survival and higher rates of radiation-related complications, which is critical for treatment planning in glioblastoma patients.
What to keep in mind
Enrollment was stopped early due to slow accrual, with only 135 patients enrolled out of the planned 474.